Optimizing Treatment of Staphylococcus aureus Bloodstream Infections Following Rapid Molecular Diagnostic Testing and an Antimicrobial Stewardship Program Intervention.
MRSA
MSSA
PCR
Staphylococcus
Xpert
outcome
stewardship
treatment
vancomycin
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
15 Feb 2023
15 Feb 2023
Historique:
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
16
2
2023
Statut:
aheadofprint
Résumé
Pending antibiotic susceptibility results, vancomycin is often used for bloodstream infections (BSIs) to ensure treatment of methicillin-resistant Staphylococcus aureus (MRSA). As rapid discrimination of methicillin-susceptible S. aureus (MSSA) from MRSA in BSIs could decrease vancomycin use and allow early optimization of beta-lactam therapy, this study evaluated the impact of the use of rapid molecular testing for MSSA and MRSA coupled with an antimicrobial stewardship program (ASP) intervention. Between January and July 2020, the Cepheid Xpert MRSA/SA blood culture assay was performed on blood cultures with Gram-positive cocci in clusters that were identified as S. aureus using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). The ASP team member then consulted with the treating physician. The time to optimal therapy (TTOT) and clinical outcomes, including length of hospital stay (LOS), were compared between the intervention (
Identifiants
pubmed: 36790177
doi: 10.1128/spectrum.01648-22
pmc: PMC10101007
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0164822Références
Diagn Microbiol Infect Dis. 2013 Feb;75(2):139-43
pubmed: 23273338
Clin Infect Dis. 2015 Aug 1;61(3):361-7
pubmed: 25900170
MMWR Morb Mortal Wkly Rep. 2019 Mar 08;68(9):214-219
pubmed: 30845118
Pathology. 2021 Dec;53(7):889-895
pubmed: 34120744
J Infect. 2013 Jul;67(1):91-2
pubmed: 23563094
Diagn Microbiol Infect Dis. 2016 Feb;84(2):159-64
pubmed: 26639226
Am J Health Syst Pharm. 2020 May 19;77(11):835-864
pubmed: 32191793
Clin Infect Dis. 2010 Nov 1;51(9):1074-80
pubmed: 20879856
J Clin Microbiol. 2013 Jun;51(6):1733-9
pubmed: 23515548
Crit Care Med. 2010 Sep;38(9):1773-85
pubmed: 20639750
Diagn Microbiol Infect Dis. 2015 Feb;81(2):96-101
pubmed: 25488272
Infect Control Hosp Epidemiol. 2010 Oct;31(10):1043-8
pubmed: 20731594
Clin Infect Dis. 2015 May 15;60(10):1451-61
pubmed: 25701854
Future Microbiol. 2020 Oct;15:1595-1605
pubmed: 33215528
Crit Care. 2010;14(5):R186
pubmed: 20950442
J Clin Microbiol. 2015 Mar;53(3):804-9
pubmed: 25540397
BMC Infect Dis. 2021 Feb 15;21(1):177
pubmed: 33588782
Pharmacoeconomics. 2010;28(7):567-75
pubmed: 20550222
Clin Microbiol Infect. 2013 Dec;19(12):E568-81
pubmed: 23890423
J Med Microbiol. 2020 Apr;69(4):552-557
pubmed: 32141812
J Clin Microbiol. 2017 May;55(5):1496-1507
pubmed: 28250000
Ir J Med Sci. 2017 Nov;186(4):995-998
pubmed: 28197879
Am J Clin Pathol. 2011 Nov;136(5):690-4
pubmed: 22031306
J Clin Microbiol. 2012 Jun;50(6):2056-8
pubmed: 22493335
J Clin Microbiol. 2012 Jan;50(1):127-33
pubmed: 22075595
J Clin Microbiol. 2019 Oct 23;57(11):
pubmed: 31484703
Open Forum Infect Dis. 2018 Oct 10;5(10):ofy258
pubmed: 30386809
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
CMAJ. 2019 Sep 3;191(35):E967
pubmed: 31481425
J Med Microbiol. 2018 Sep;67(9):1253-1256
pubmed: 30028662
J Clin Microbiol. 2017 May;55(5):1437-1445
pubmed: 28228491
Diagn Microbiol Infect Dis. 2014 Apr;78(4):352-5
pubmed: 24503507
J Pediatric Infect Dis Soc. 2017 Sep 01;6(3):267-274
pubmed: 27543412
J Clin Microbiol. 2016 Oct;54(10):2455-63
pubmed: 27487951